Delivering functional genes into cells to replace mutated genes, an approach known as gene therapy, holds potential for treating many types of diseases. The earliest efforts to deliver genes to diseased cells focused on DNA, but many scientists are now exploring the possibility of using RNA instead, which could offer improved safety and easier delivery.
MIT biological engineers have now devised a way to regulate the expression of RNA once it gets into cells, giving them precise control over the dose of protein that a patient receives. This technology could allow doctors to more accurately tailor treatment for individual patients, and it also offers a way to quickly turn the genes off, if necessary.
“We can control very discretely how different genes are expressed,” says Jacob Becraft, an MIT graduate student and one of the lead authors of the study, which appears in the Oct. 16 issue of Nature Chemical Biology. “Historically, gene therapies have encountered issues regarding safety, but with new advances in synthetic biology, we can create entirely new paradigms of ‘smart therapeutics’ that actively engage with the patient’s own cells to increase efficacy and safety.”
Becraft and his colleagues at MIT have started a company to further develop this approach, with an initial focus on cancer treatment. Tyler Wagner, a recent Boston University PhD recipient, is also a lead author of the paper. Tasuku Kitada, a former MIT postdoc, and Ron Weiss, an MIT professor of biological engineering and member of the Koch Institute, are senior authors.
Only a few gene therapies have been approved for human use so far, but scientists are working on and testing new gene therapy treatments for diseases such as sickle cell anemia, hemophilia, and congenital eye disease, among many others.
As a tool for gene therapy, DNA can be difficult to work with. When carried by synthetic nanoparticles, the particles must be delivered to the nucleus, which can be inefficient. Viruses are much more efficient for DNA delivery; however, they can be immunogenic, difficult, and expensive to produce, and often integrate their DNA into the cell’s own genome, limiting their applicability in genetic therapies.
Messenger RNA, or mRNA, offers a more direct, and nonpermanent, way to alter cells’ gene expression. In all living cells, mRNA carries copies of the information contained in DNA to cell organelles called ribosomes, which assemble the proteins encoded by genes. Therefore, by delivering mRNA encoding a particular gene, scientists can induce production of the desired protein without having to get genetic material into a cell’s nucleus or integrate it into the genome.
To help make RNA-based gene therapy more effective, the MIT team set out to precisely control the production of therapeutic proteins once the RNA gets inside cells. To do that, they decided to adapt synthetic biology principles, which allow for precise programming of synthetic DNA circuits, to RNA.
The researchers’ new circuits consist of a single strand of RNA that includes genes for the desired therapeutic proteins as well as genes for RNA-binding proteins, which control the expression of the therapeutic proteins.
“Due to the dynamic nature of replication, the circuits’ performance can be tuned to allow different proteins to express at different times, all from the same strand of RNA,” Becraft says.
This allows the researchers to turn on the circuits at the right time by using “small molecule” drugs that interact with RNA-binding proteins. When a drug such as doxycycline, which is already FDA-approved, is added to the cells, it can stabilize or destabilize the interaction between RNA and RNA-binding proteins, depending on how the circuit is designed. This interaction determines whether the proteins block RNA gene expression or not.
In a previous study, the researchers also showed that they could build cell-specificity into their circuits, so that the RNA only becomes active in the target cells.
The company that the researchers started, Strand Therapeutics, is now working on adapting this approach to cancer immunotherapy — a new treatment strategy that involves stimulating a patient’s own immune system to attack tumors.
Using RNA, the researchers plan to develop circuits that can selectively stimulate immune cells to attack tumors, making it possible to target tumor cells that have metastasized to difficult-to-access parts of the body. For example, it has proven difficult to target cancerous cells, such as lung lesions, with mRNA because of the risk of inflaming the lung tissue. Using RNA circuits, the researchers first deliver their therapy to targeted cancer cell types within the lung, and through their genetic circuitry, the RNA would activate T-cells that could treat the cancer’s metastases elsewhere in the body.
“The hope is to elicit an immune response which is able to pick up and treat the rest of the metastases throughout the body,” Becraft says. “If you’re able to treat one site of the cancer, then your immune system will take care of the rest, because you’ve now built an immune response against it.”
Using these kinds of RNA circuits, doctors would be able to adjust dosages based on how the patient is responding, the researchers say. The circuits also provide a quick way to turn off therapeutic protein production in cases where the patient’s immune system becomes overstimulated, which can be potentially fatal.
In the future, the researchers hope to develop more complex circuits that could be both diagnostic and therapeutic — first detecting a problem, such as a tumor, and then producing the appropriate drug.
The Latest on: RNA circuits
via Google News
The Latest on: RNA circuits
- Combining deep computational learning and synthetic biologyon December 1, 2020 at 8:19 am
Dr Diogo Camcho discusses synthetic biology research into machine learning algorithms to analyse RNA sequences and reveal drug targets.
- Potential New Therapies for Alzheimer’s Disease are Revealed through Network Modeling of Its Complex Molecularon November 24, 2020 at 4:26 pm
Researchers from Mount Sinai and the National Center for Geriatrics and Gerontology in Japan have identified new molecular mechanisms driving ...
- Zoombombing, superspreader, covidiot: Oxford Word of the Year is expanded to a whole LIST for 2020 to capture mood of an 'unprecedented' 12 monthson November 23, 2020 at 4:21 am
The 'Words of an Unprecedented Year' report also includes lockdown, circuit-breaker and Zoombombing ... any of a group of RNA viruses that cause a variety of respiratory, gastrointestinal ...
- Brain mapping, from molecules to networkson November 19, 2020 at 2:55 pm
Single-cell RNA sequencing revealed that these neurons formed a single ... How do thirst-sensitive neurons deep in the brain coordinate activity in distributed circuits spanning sensory perception, ...
- Moderna's Preliminary Results Indicate That Its COVID-19 Vaccine Is 94.5% Effectiveon November 16, 2020 at 9:35 am
Moderna released the preliminary results from its ongoing clinical trial of its messenger RNA (mRNA) vaccine today, reporting that it is 94.5 percent effective at preventing COVID-19 infection.
- Exploring the Role of Long Non-Coding RNA in Cancer Developmenton November 16, 2020 at 2:58 am
News Nov 16, 2020 | Original story from Duke-NUS Medical School A group of researchers has discovered a genetic program essential for the formation of bilateral circuits, such as the one that makes ...
- A Zic2-regulated switch in a noncanonical Wnt/βcatenin pathway is essential for the formation of bilateral circuitson November 13, 2020 at 11:58 am
Short hairpin RNA against βcatenin (ctnnb1 shRNA) (fig. S2) was injected and electroporated into the retinas of E13.5 mouse embryos, and the axonal projection phenotype of targeted neurons at the ...
- Northern Ireland 'circuit-breaker' lockdown extendedon November 12, 2020 at 2:18 pm
Pubs will have to remain closed. Picture: PA Sinn Fein voted against the proposal because it ran contrary to the guidance from Stormont's medical and scientific advisers to extend the circuit-break in ...
- Breaking Down Moderna’s COVID-19 Patent Pledge: Why Did They Do It?on November 11, 2020 at 1:16 pm
“Moderna’s COVID-19 pledge positions it well to grow the new mRNA market its business is founded upon, capitalize on licensing deals, and restore all enforcement rights “post pandemic.” ...
via Bing News